Aileron Overcoming Spirited Debate About Stapled Peptides
This article was originally published in The Pink Sheet Daily
Executive Summary
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.
You may also be interested in...
Aileron Raises $30M From Existing Investors To Advance Pair Of Stapled Peptide Candidates
The Cambridge, Mass., biotech plans to bring a candidate for cancer into clinical development next year, while starting Phase Ib dose-finding research with its endocrinology disorder candidate.
Heptares And Complix Raise Series B Funds To Advance Preclinical Compounds
GPCR-focused Heptares and the protein scaffold company Complix complete a seemingly rare event for European biotechs, a second round of VC funding.
Pharma Deals That Generate Lasting Value: A Roundtable Discussion
At Elsevier Business Intelligence's recent Therapeutic Area Partnerships conference, a roundtable of senior pharmaceutical executives and entrepreneurs weighed in on industry’s current funding challenges, how dealmaking defines a biotech’s ambitions and strategy, and pharma’s appetite for early-stage innovation.